Gossypol enhances ponatinib's cytotoxicity against human hepatocellular carcinoma cells by involving cell cycle arrest, p-AKT/LC3II/p62, and Bcl2/caspase-3 pathways.

Toxicol Rep · 2025 · PMC11719416 · PMID 39802605

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

marginally non-significantP > 0.05actually significant

Furthermore, gossypol caused a 3.44-fold rise in p62 protein levels, but ponatinib demonstrated a marginally non-significant increase ( P > 0.05).

also in 274 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.